Want to see ADCT full AI Analyst Report?
ADC Therapeutics (ADCT) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Loncastuximab Tesirine | Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma | Phase I | Recruiting | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) | Dec 13, 2022 | ― |
| Gemcitabine, Adct-601 | Advanced Solid Tumors | Phase I | Terminated | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | May 20, 2022 | ― |
| Rituximab, Loncastuximab Tesirine | Diffuse Large B-Cell Lymphoma | Phase II | Terminated | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | Nov 22, 2021 | ― |
| Adct-901 | Advanced Solid Tumors | Phase I | Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Jul 13, 2021 | ― |
| Obinutuzumab, Loncastuximab Tesirine, Glofitamab, Polatuzumab Vedotin, Mosunetuzumab | B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma | Phase I | Recruiting | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Jul 12, 2021 | ― |
| Gemcitabine, Rituximab, Oxaliplatin, Loncastuximab Tesirine | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase III | Active Not Recruiting | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | May 08, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Loncastuximab Tesirine | Phase I | Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma | Recruiting | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) | Dec 13, 2022 | ― |
| Gemcitabine, Adct-601 | Phase I | Advanced Solid Tumors | Terminated | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | May 20, 2022 | ― |
| Rituximab, Loncastuximab Tesirine | Phase II | Diffuse Large B-Cell Lymphoma | Terminated | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | Nov 22, 2021 | ― |
| Adct-901 | Phase I | Advanced Solid Tumors | Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Jul 13, 2021 | ― |
| Obinutuzumab, Loncastuximab Tesirine, Glofitamab, Polatuzumab Vedotin, Mosunetuzumab | Phase I | B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma | Recruiting | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Jul 12, 2021 | ― |
| Gemcitabine, Rituximab, Oxaliplatin, Loncastuximab Tesirine | Phase III | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Active Not Recruiting | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | May 08, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does ADC Therapeutics Ltd (ADCT) have in its pipeline
ADC Therapeutics ADCT is currently developing the following drugs: Loncastuximab Tesirine, Gemcitabine, Adct-601, Rituximab, Loncastuximab Tesirine, Adct-901, Obinutuzumab, Loncastuximab Tesirine, Glofitamab, Polatuzumab Vedotin, Mosunetuzumab, Gemcitabine, Rituximab, Oxaliplatin, Loncastuximab Tesirine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.